Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, T-Cell, Peripheral 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × Immunoconjugates × Clear all
NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Terminated
1 enrolled 5 charts
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡